Search company, investor...
Cavadis company logo

Cavadis

cavadis.com

Founded Year

2007

Stage

Series A | Alive

About Cavadis

biomedical company focused on discovering imaging biomarkers, developing molecular diagnostics and identifying therapeutic targets for atherosclerotic disease.

Headquarters Location

Dr. Molewaterplein 50 Kamer EE 19-14

Netherlands

Missing: Cavadis's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Cavadis's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Cavadis Frequently Asked Questions (FAQ)

  • When was Cavadis founded?

    Cavadis was founded in 2007.

  • What is Cavadis's latest funding round?

    Cavadis's latest funding round is Series A.

  • Who are the investors of Cavadis?

    Investors of Cavadis include Erasmus MC Biomedical Fund and Thuja Capital Management.

  • Who are Cavadis's competitors?

    Competitors of Cavadis include e-therapeutics, Carmot Therapeutics, Five Prime Therapeutics, Melior Discovery, Echelon Biosciences and 10 more.

Compare Cavadis to Competitors

Echelon Biosciences Logo
Echelon Biosciences

Echelon Biosciences is a company that received a SBIR Phase I grant for a project entitled: Near Infrared Substrates for Imaging Autotaxin Activity In Vivo. Their project aims to synthesize ATXRed, an in vivo imaging agent that is specifically activated by the enzymatic activity of autotaxin. Autotaxin is an extracellular enzyme that generates the phospholipid growth factor lysophophatidic acid (LPA). LPA is involved in a variety of biological functions, such as angiogenesis, wound healing, brain development, immunological competence and the regulation of blood pressure. Both LPA and autotaxin have also been implicated in numerous diseases, especially metastatic cancer. Autotaxin was identified as one of the 40 most induced genes in aggressive breast cancer. The broader impacts of this research are the discovery and commercialization of tools that easily highlight specific biological pathways in living organisms. ATXRed will be welcomed by basic researchers in many fields associated with autotaxin and LPA. However, the utility extends beyond the basic research sphere. ATXRed smart probes could also aid pharmaceutical researchers searching for pharmacological inhibitors of autotaxin and LPA receptor agonists and antagonists. ATXRed would be a powerful tool in many rodent models of human cancer. In vivo autotaxin imaging probes could also aid in the clinic by helping to identify and monitor disease progression and treatment. Ultimately, ATXRed could help guide surgical resection of tumorstumors previously identified by the smart probe to have elevated autotaxin activity. In total, ATXRed probes have the potential to impact basic research, drug discovery and the clinic as a prime example of molecular medicine applied from bench to bedside.

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

A
Amura

Amura is a structure-based drug discovery business specialising in diseases such as osteoporosis, bone metastasis, autoimmunity, chronic pain and malaria. Amura has a scaffold (AMcore) that aims to provide a turnkey solution for the discovery of small-molecule inhibitors against cysteine peptidases (e.g. cathepsin enzymes); which are commercially attractive therapeutic targets

V
VivoPath

VivoPath is a preclinical screening company, offering the company's clients discovery and development services for in vivo testing. VivoPath aims to provide integrated in vivo studies led by established experts in drug development. Efficacy is established for animal models in the areas of metabolic disease, inflammation, neurodegenerative disease, and infectious diseases. Formulation screening is carried out to select the most appropriate delivery system for administration. Pharmacokinetic evaluation is carried out to assess exposure and bioavailability. Tolerability is assessed with evaluations of clinical signs, clinical chemistry and hematology. The resulting program aims to deliver the client an in vivo therapeutic index (TI) report on which to assess candidates for subsequent development. VivoPath can also help clients at any individual step in this preclinical screening process. VivoPath's commitment is to provide scientific expertise in in vivo drug discovery in order to increase productivity from research into drug development.

B
Biomedica Management

Biomedica Management Corporation is a Small Business Disadvantaged Company 8(a) certified by the Small Business Administration, operating in the field of the biomedical sciences and research & development. Biomedica signed a CRADA agreement with US Army Institute for Surgical Research to study an intracaviray hemostatic agent for use in the battlefield. The study was funded by TEDCO, and a second round of funding is assured by Johnson & Johnson.

H
Hummune

Hummune Solutions has developed a human- mouse platform "˜ChimMouse' which expresses a functional human immune system that can be modulated to produce human antibodies in both composition and context. With its long term objective of becoming a major player in the areas of therapeutic human mAbs, generic biologicals and personalized medicine, the company has a strategic business model in place that will allow the pursuance of short term objectives without losing the focus of the primary market. With its "ChimMouse Advantage" the company will provide custom research grade human antibodies and drug/vaccine testing services. The revenue generated will be invested in its subsequent development of biotherapeutics. A research sharing program with academic researchers to use the ChimMouse as an animal model will also be in place. This will potentially enrich the company's R&D portfolio in addition to providing credibility to the technology platform.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.